Physician profile
Elliott James
NPI 1649778309
$14,397.58
in general payments reported to CMS, 2019-2025
60 companies · $3,900 in 2025
The $3,900 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,185 · 2022: $1,987 · 2023: $2,875 · 2024: $3,451 · 2025: $3,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,180.78 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,162.24 | 2021-2025 | |
| Ucb, INC. | $875.26 | 2021-2025 | Nayzilam, Rystiggo, Briviact |
| Emd Serono, INC. | $839.80 | 2021-2025 | Mavenclad |
| Biogen, INC. | $790.32 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $758.25 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $687.73 | 2023-2025 | Ingrezza, Ongentys |
| Amgen INC. | $584.69 | 2021-2025 | Uplizna |
| Lilly USA, LLC | $510.32 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $496.84 | 2021-2025 | |
| Lundbeck LLC | $431.03 | 2021-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $422.35 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $415.37 | 2021 | |
| Pfizer INC. | $319.57 | 2023-2025 | |
| Horizon Therapeutics Plc | $314.85 | 2021-2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $286.90 | 2021-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $285.73 | 2021-2025 | Hyqvia, Gammagard Liquid |
| Alexion Pharmaceuticals, INC. | $269.07 | 2023-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $263.37 | 2021-2024 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $255.29 | 2022 | |
| Tg Therapeutics, INC. | $253.46 | 2023-2025 | |
| Genentech USA, INC. | $216.78 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Otsuka America Pharmaceutical, INC. | $203.76 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $192.63 | 2021-2025 | Crexont, Rytary |
| Jazz Pharmaceuticals INC. | $168.21 | 2021-2025 | Epidiolex |
| Sumitomo Pharma America, INC. | $167.52 | 2023-2024 | Aptiom |
| Argenx US, INC. | $167.16 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $156.48 | 2024-2025 | Ponvory |
| Catalyst Pharmaceuticals, INC. | $148.62 | 2024-2025 | |
| Neurelis, INC. | $144.86 | 2024-2025 | Valtoco |
| Scilex Pharmaceuticals INC. | $141.25 | 2022-2024 | Ztlido |
| Biotronik INC. | $140.38 | 2025 | Biomonitor |
| Sk Life Science, INC. | $135.80 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $96.88 | 2021 | |
| Alnylam Pharmaceuticals INC. | $85.62 | 2023 | Onpattro |
| Acorda Therapeutics, INC | $82.11 | 2021-2023 | Inbrija, Ampyra |
| Banner Life Sciences, LLC | $72.78 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $72.71 | 2021-2025 | Qelbree |
| Livanova USA, INC. | $69.13 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $69.05 | 2023-2025 | Gamunex-C |
| Life Molecular Imaging LTD | $64.66 | 2024-2025 | Neuraceq |
| Csl Behring | $61.77 | 2024 | Hizentra |
| Avadel Cns Pharmaceuticals, LLC | $53.05 | 2025 | Lumryz |
| Axsome Therapeutics, INC. | $49.33 | 2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $44.97 | 2021-2025 | Acthar |
| Janssen Pharmaceuticals, INC | $41.47 | 2024-2025 | Spravato |
| Boston Scientific Corporation | $41.10 | 2023-2024 | |
| Silk Road Medical, INC. | $38.43 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Ge Healthcare | $25.05 | 2023 | |
| Aucta Pharmaceuticals, INC. | $24.80 | 2025 | Motpoly Xr |
| Averitas Pharma INC. | $24.58 | 2023 | Qutenza |
| Upsher-Smith Laboratories LLC | $23.82 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.42 | 2025 | Keveyis |
| Janssen Biotech, INC. | $21.14 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.59 | 2022 | |
| Kyowa Kirin, INC. | $15.93 | 2021 | |
| Impel Pharmaceuticals LLC | $15.31 | 2025 | Trudhesa |
| Inspire Medical Systems, INC. | $15.20 | 2025 | Inspire |
| Corium, LLC | $14.69 | 2023 | Adlarity |
| Arbor Pharmaceuticals, INC. | $13.10 | 2021 | |
| Allergan, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliott James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.